Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124
Ritter A, Mellor R, Chalmers J, Sunderland M, Lancaster K. Key considerations in planning for substance use treatment: estimating treatment need and demand. J Stud Alcohol Suppl. 2019 Jan;Supp1 18:22-30. doi: 10.15288/jsads.2019.s18.22
Heidenreich S, Watson V, Ryan M, Phimister E. Decision heuristic or preference? Attribute non-attendance in discrete choice problems. Health Econ. 2018 Jan;27(1):157-71. doi: 10.1002/hec.3524
Tsuchiya A, Watson V. Re-thinking “the different perspectives that can be used when eliciting preferences in health". Health Econ. 2017 Dec;26(12):e103-7. doi: 10.1002/hec.3480
Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017 Dec;26(12):e1-e16. doi: 10.1002/hec.3459
Watson V, Becker F, de Bekker-Grob E. Discrete choice experiment response rates: a meta-analysis. Health Econ. 2017 Jun;26(6):810-7. doi: 10.1002/hec.3354
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin. 2014 Feb;32(2):70-5. doi: 10.1016/j.eimc.2013.02.009
Smets E, Brogan AJ, Hill A, Adriaenssen I, Sawyer AW, Domingo-Pedrol P, Gostkorzewicz J, Ledesma F. Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain. Enferm Infecc Microbiol Clin. 2013 Aug;31(7):430-6.
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Houser KA, Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012 Jun;21(6):633-52.
Serna MC, Real J, Ribes E, Marsal JR, Godoy P, Galvin L. Factors determining antibiotic prescription in primary care. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):193-200. doi: 10.1016/j.eimc.2010.09.012
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.
Anthony M, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. J. Med. Food. 1999;2(3-4):263-6.